Structure-based design of human pancreatic amylase inhibitors from the natural anthocyanin database for type 2 diabetes

2020 ◽  
Vol 11 (4) ◽  
pp. 2910-2923 ◽  
Author(s):  
Lianghua Xie ◽  
Jianling Mo ◽  
Jingdan Ni ◽  
Yang Xu ◽  
Hongming Su ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Design Approach ◽  
Pancreatic Amylase ◽  
Amylase Inhibitor ◽  
Amylase Inhibitors

Malvidin 3-O-arabinoside is identified as a novel human pancreatic amylase inhibitor from the natural anthocyanin database with a structure-based design approach.

scholarly journals Potential compounds phenolic group sawo leaves (Manilkara zapota) as an α-amylase inhibitor in type 2 diabetes mellitus by in silico

2021 ◽  
Author(s):  
Siti Imroatul Maslikah ◽  
Rif'atul Chusnul Khuluq ◽  
Ilfia Kholifaturrohmah ◽  
Lintang Miftahul Rizki ◽  
Atikah Amalia
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
In Silico ◽  
Manilkara Zapota ◽  
Amylase Inhibitor ◽  
Phenolic Group

scholarly journals The Effect of Bioactive Polyphenols from Anacardium occidentale Linn. Leaves on α-Amylase and Dipeptidyl Peptidase IV Activities

2020 ◽  
Vol 20 (5) ◽  
pp. 1010
Author(s):  
Nur Imanina Abdullah Thaidi ◽  
Hanapi Mat Jusoh ◽  
Ahmad Badruddin Ghazali ◽  
Deny Susanti ◽  
Normah Haron
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Inhibitory Effect ◽  
Dipeptidyl Peptidase Iv ◽  
Anacardium Occidentale ◽  
Mature Leaves ◽  
Young Leaves ◽  
Amylase Inhibitors

Anacardium occidentale Linn. (A. occidentale L.) leaves possess bioactive polyphenols which are associated with antidiabetic potency for the management of type 2 diabetes mellitus (T2DM). In this study, free, soluble ester, and insoluble-bound phenolic fractions from young and mature leaves of A. occidentale L. were extracted. Subsequently, all fractions were investigated for their inhibitory effect on α-amylase and dipeptidyl peptidase IV (DPPIV) activities. Both free (72.45 ± 3.6%) and soluble ester (83.40 ± 4.7%) phenolic fractions in the mature leaves extracts had significantly demonstrated greater α-amylase inhibitors than the young leaves. Likewise, soluble ester (4.09 ± 0.34 µg/mL) and insoluble-bound (4.87 ± 0.32 µg/mL) phenolic fractions in the mature leaves extracts were significantly more effective in inhibiting DPPIV than the young leaves. As for fractions comparison, insoluble-bound derived from the young leaves extract was a more potent α-amylase inhibitor than free and soluble ester phenolic fractions (p < 0.0001). Besides, soluble ester and insoluble-bound phenolic fractions showed a stronger inhibitor of DPPIV than the free phenolic (p < 0.001), irrespective of the maturity of the leaves. In conclusion, this study showed that A. occidentale L. extracts possessed antidiabetic properties, which may potentially be used as an alternative treatment for T2DM management.

scholarly journals The effect of a human pancreatic α‐amylase inhibitor, montbretin A, on the chronic treatment of type 2 diabetes

2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Violet G. Yuen ◽  
Gary Brayer ◽  
Stephen Withers ◽  
Raymond Andersen ◽  
John Coleman ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Treatment ◽  
Amylase Inhibitor

scholarly journals Magnificamide is a new effective mammalian a-amylase inhibitor

2019 ◽  
Vol 489 (4) ◽  
pp. 429-432
Author(s):  
O. V. Sintsova ◽  
E. V. Leychenko ◽  
I. N. Gladkikh ◽  
A. P. Kalinovskii ◽  
M. M. Monastyrnaya ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Kinetic Parameters ◽  
Metabolic Disorders ◽  
Amylase Inhibitor ◽  
Prevention And Treatment ◽  
Heteractis Magnifica ◽  
Medical Drug

Recombinant analog of sea anemone Heteractis magnifica peptide was obtained and kinetic parameters of its interaction with mammalian -amylases were determined. Magnificamide inhibits -amylases significantly stronger than a medical drug acarbose (PrecoseTM or GlucobayTM). Magnificamide is assumed to find application as a drug for prevention and treatment of metabolic disorders and type 2 diabetes mellitus.

scholarly journals Study of Serum Pancreatic Amylase and Lipase Enzyme in Patients with Type 2 Diabetes

2021 ◽  
pp. 197-201
Author(s):  
Gangaram Bhadarge ◽  
Pratibha Dawande ◽  
Nandkishor Bankar ◽  
Raunak Kotecha
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Acinar Cells ◽  
Research Centre ◽  
Exocrine Function ◽  
Diabetic Patients ◽  
Pancreatic Amylase ◽  
Type 2 Diabetic Patients ◽  
Lipase Enzyme

Introduction: Diabetes mellitus (DM) is a metabolic disorder that is greatly exacerbated by a complete lack of insulin or insulin resistance. The pancreas is a multicellular organ, the exocrine half accounting for 84% of its volume and the endocrine half accounting for only 2%. Since these two parts of the world have a close relationship with structure and function, the disruption of one can affect the other. Hemoglobin A1C (HbA1c) represents the glycemic status of the patient over the previous three months. Evidence suggests that pancreatic endocrine hormones, especially insulin, affect pancreatic exocrine function. Insulin has a detrimental effect on exocrine acinar cells. Exocrine acinar cells attached to it contain a variety of enzymes, including amylase and lipase, which help digest certain food particles. Aim: Study of serum pancreatic amylase and lipase enzyme in patients with type 2 diabetes. Materials and Methods: This cross sectional study was done in the Department of Biochemistry, dept. of medicine and Diabetic OPD, Datta Meghe Medical College and Shalinitai Meghe Hospital and Research Centre, Nagpur. For this study 40 diagnosed type 2 diabetic patients of both sexes with age ranging 35-60 years were selected as study group. Results: FBS, HbA1C, serum pancreatic amylase, and lipase mean effects between control and patients showed statistically significant differences in type 2 diabetes mellitus (P <0.0001). Conclusion: We concluded that pancreatic amylase and lipase function are impaired in type 2 patients with diabetes, and this observation is particularly important in type 2 diabetes. It has been suggested that the analysis of pancreatic enzymes in diabetic patients may be a useful parameter in determining the progression of the disease.

An Insight of Alpha-amylase Inhibitors as a Valuable Tool in the Management of Type 2 Diabetes Mellitus

2020 ◽  
Vol 16 (2) ◽  
pp. 117-136 ◽  
Author(s):  
Roqia Bashary ◽  
Manish Vyas ◽  
Surendra Kumar Nayak ◽  
Ashish Suttee ◽  
Surajpal Verma ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Alpha Amylase ◽  
Antidiabetic Agents ◽  
Scientific Database ◽  
New Therapeutic Approaches ◽  
Good Target ◽  
Amylase Inhibitors

Background: Among the millions of people around the world, the most prevalent metabolic disorder is diabetes mellitus. Due to the drawbacks which are associated with commercially available antidiabetic agents, new therapeutic approaches are needed to be considered. Alpha-amylase is a membrane- bound enzyme which is responsible for the breakdown of polysaccharides such as starch to monosaccharides which can be absorbed. Methods: We searched the scientific database using alpha-amylase, diabetes, antidiabetic agents as the keywords. Here in, only peer-reviewed research articles were collected which were useful to our current work. Results: To overcome the research gap, the alpha-amylase enzyme is regarded as a good target for antidiabetic agents to design the drug and provide an alternate approach for the treatment of type 2 diabetes mellitus. Basically, alpha-amylase inhibitors are classified into two groups: proteinaceous inhibitors, and non-proteinaceous inhibitors. Recently, non-proteinaceous inhibitors are being explored which includes chalcones, flavones, benzothiazoles, etc. as the potential antidiabetic agents. Conclusion: Herein, we discuss various potential antidiabetic agents which are strategically targeted alpha-amylase enzyme. These are having lesser side effects as compared to other antidiabetic agents, and are proposed to prevent the digestion and absorption of glucose leading to a decrease in the blood glucose level.

Pouteria torta epicarp as a useful source of α-amylase inhibitor in the control of type 2 diabetes

2017 ◽  
Vol 109 ◽  
pp. 962-969 ◽  
Author(s):  
Paloma Michelle de Sales ◽  
Paula Monteiro de Souza ◽  
Mariana Dartora ◽  
Inês Sabioni Resck ◽  
Luiz Alberto Simeoni ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Amylase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document